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 Abstract 
 Background: Obesity treatments aim to maximize fat loss, 
particularly abdominal or visceral fat, without compro-
mising lean or bone mass. However, the literature con-
tains numerous examples of obesity treatments that  – in 
addition to fat loss  – result in loss of lean mass and/or 
bone mass. 
 Materials and methods: Because of the known effects of 
energy restriction to increase activity of the hypothalamo-
pitutiary adrenal (HPA) axis in lean humans and animals, 
and because increases in circulating glucocorticoid levels 
could potentially contribute to adverse body composi-
tional changes with obesity treatments, we conducted a 
systematic PubMed search to determine whether HPA axis 
activation also occurs in response to energy restriction in 
obese humans and animals. 
 Results and conclusions: In most studies in obese hu-
mans, short-term severe energy restriction increased cir-
culating cortisol levels, and this response was also seen 
in two longer-term human studies involving severe or mo-
derate energy restriction. These fi ndings parallel studies 
on short- or long-term energy restriction in obese rodents, 
with most studies showing increases in circulating corti-
costerone concentrations, and no change or actual increa-
ses in hypothalamic expression of corticotropin-releasing 
hormone, urocortin 3 or their receptors. However, a signi-
fi cant proportion of studies involving longer-term severe 
or moderate energy restriction in obese humans showed 
no change or decreases in HPA axis function. There was 
variability among human studies in the duration of ener-
gy restriction and timing of the HPA axis investigations 
(i.e., during energy restriction, or aft er a period of post-re-
striction weight maintenance). In order to unambiguously 
determine changes in HPA axis function with energy re-
striction in obese humans, it will be important to assess 
HPA axis function at multiple time points  during energy 
restriction, given that obese individuals may spend many 
weeks or months in severe or moderate energy restriction 
in order to reduce excess weight, and given that increases 
in glucocorticoid function can have signifi cant eff ects on 
body composition within weeks to months. 
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 Introduction 
 Obesity is a condition defined as abnormal or excessive fat 
accumulation and has been identified as a risk factor for 
a number of disorders, including type 2 diabetes [1] and 
cardiovascular diseases [2]. The worldwide prevalence of 
obesity continues to increase and has more than doubled 
since 1980. 
 An important aspect of curbing the impact of the 
obesity epidemic is providing effective long-term treat-
ments. The aim of obesity treatments is to maximize the 
loss of fat mass, particularly abdominal or visceral fat 
mass, without compromising lean body mass or bone 
mass. However, the literature contains numerous exam-
ples of obesity treatments that  – in addition to induc-
ing fat loss  – result in loss of lean mass and/or bone 
mass, particularly when supervised strength training is 
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not incorporated into the treatment regime [3 – 7], when 
dietary protein intake falls below certain critical levels [8], 
and possibly also when weight loss is rapid, as in severely 
energy-restricted diets [9], or as a result of some forms 
of bariatric surgery [10]. Understanding the mechanisms 
underpinning changes in body composition in response 
to obesity treatments could lead to improved clinical out-
comes from such treatments. 
 We hypothesise that increased activity of the hypo-
thalamo-pituitary-adrenal (HPA) axis in response to 
energy restriction in obese people may contribute to less 
than optimal body compositional outcomes. The ration-
ale for this hypothesis is that energy restriction in lean 
humans or animals is known to up-regulate activity of 
the HPA axis, with resultant increases in circulating 
glucocorticoid levels [11]. Moreover, because glucocorti-
coids per se can cause accretion of white adipose tissue 
 – particularly visceral adipose tissue  – as well as loss of 
lean tissue and bone mass in humans and animals, such 
increases in circulating glucocorticoid levels probably 
contribute to the loss of lean tissue and bone in severely 
energy-restricted people (e.g., patients with anorexia 
nervosa or elite gymnasts), as well as the preferen-
tial accretion of central fat with re-feeding in anorexia 
nervosa [11]. One might argue that an obese individual 
undergoing energy restriction to lose excess weight is 
under a less extreme form of nutritional stress than an 
already lean or underweight individual in severe energy 
restriction caused by anorexia nervosa or competitive 
sports requirements. However, because obesity per se is 
already associated with heightened activity of the HPA 
axis, as will be briefly discussed below, any effects of 
energy restriction on HPA axis activity in obesity may not 
be negligible. 
 In light of these considerations, we conducted a sys-
tematic search of the literature in the PubMed database 
from 1975 to June 2013 in order to ascertain the effects 
of energy restriction on activity of the HPA axis in obese 
animals and humans. Our search strategy included the 
following Medical Subject Heading (MeSH) terms: [diet, 
reducing OR diet, weight loss OR caloric restriction OR 
obesity/diet therapy OR food deprivation OR body weight 
(only in animal search)] AND [corticotropin-releasing 
hormone OR receptors, corticotropin-releasing hormone 
OR corticotroph OR receptors, corticotropin OR glucocorti-
coid OR receptors, glucocorticoid OR adrenocorticotropic 
hormone OR hydrocortisone OR corticosterone OR cortico-
releasing factor (only in animal search)] AND (obesity). 
We limited our search to articles in English and studies in 
humans and animals. The search yielded 105 human and 
741 animal articles. We retrieved the full text and reviewed 
in depth only those articles that included investigation of 
the effect of energy restriction on the HPA axis in obese 
humans or animals (mice and rats), as stated in the article 
title or abstract. Sixteen human and 10 animal articles met 
these criteria and were thus included in our review. These 
articles are cited in the sections below entitled  “ Effects 
of energy restriction on activity of the HPA axis in obese 
humans ” , and  “ Effects of energy restriction on activity of 
the HPA axis in obese rodents ” . 
 Before outlining the results of our systematic litera-
ture search, we will first provide an overview of the HPA 
axis, as well as the effects of obesity per se and eating 
on activity of this axis, as this provides important back-
ground to our literature review. 
 Overview of the HPA axis 
 The HPA axis is a major neuroendocrine system that helps 
to protect against stressors by regulating the secretion of 
glucocorticoids [12]. Stress induces the release of cortico-
tropin-releasing hormone (CRH) from the paraventricular 
nucleus (PVN) of the hypothalamus. CRH is released into 
the hypophyseal portal system and is transported to the 
pars distalis in the anterior lobe of the pituitary gland, 
where it stimulates the secretion of adrenocorticotropin 
(ACTH) from the anterior pituitary. ACTH, in turn, stimu-
lates glucocorticoid production from the adrenal cortex, 
and glucocorticoids are transported in the circulation 
bound to corticosteroid-binding globulin (CBG). The avail-
ability of glucocorticoids in target tissues is dependent on 
activity of the enzyme 11 β -hydroxysteroid dehydrogenase 
(11 β -HSD). The 11 β -HSD1 isoform converts the inactive 
glucocorticoids (cortisone in humans and 11-dehydrocor-
ticosterone in rodents) into their active form (cortisol in 
humans and corticosterone in rodents), and the 11 β -HSD2 
isoform inactivates cortisol and corticosterone [13]. Gluco-
corticoids exert actions in target tissues by binding to and 
activating the glucocorticoid receptor. Glucocorticoids 
participate in the control of whole body homeostasis and 
the response to stress, and play a key role in regulating 
basal activity of the HPA axis. The glucocorticoid recep-
tor initiates or represses gene transcription, and induces 
negative feedback of the HPA axis, for termination of the 
stress response, by acting on the hypothalamus and the 
pituitary gland [14]. The inhibitory glucocorticoid feed-
back on the HPA axis limits duration of the total tissue 
exposure to glucocorticoids, thus minimizing catabolic, 
anti-reproductive and immunosuppressive effects of these 
hormones. 
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 Obesity is associated with 
 dysregulation of the HPA axis 
 Previous studies have shown that obesity is associated 
with HPA axis dysregulation that may originate from 
increased forward drive, decreased sensitivity to negative 
feedback regulation, or altered sensitivity of peripheral 
tissues such as fat and skeletal muscle tissue to gluco-
corticoids [15, 16]. Obese humans show a hypersensitive 
response to stimulation of the HPA axis, the magnitude of 
this exaggerated response being dependent on fat distri-
bution [17, 18]. After physical or psychological stressors, or 
after exogenous administration of CRH, obese individuals 
showed exaggerated circulating ACTH and glucocorticoid 
levels [17, 19]. This exaggerated response was significantly 
greater in those obese people who have a more visceral 
distribution of body fat than those with a more subcuta-
neous distribution [17]. Greater visceral adiposity is also 
associated with a higher HPA axis response in lean people 
[19]. Sex also plays an important role in determining HPA 
axis response, where cortisol exposure is inversely related 
to fat mass index (calculated as fat mass/height 2 in kg/m 2 ) 
in men and waist to hip ratio in women [18, 20 – 23]. 
 While the exact direction(s) of causality in this asso-
ciation between visceral adiposity and HPA response is 
unclear, the relationship may be caused by the physiology 
of visceral fat, which contains a higher density of glucocor-
ticoid receptors than subcutaneous fat without an increase 
in binding affinity [24]. This could in turn influence glu-
cocorticoid production and subsequent negative feedback 
to the brain. Indeed, it has been shown that people with a 
greater visceral fat distribution may have increased pitui-
tary sensitivity to CRH [18]. Another factor that may contrib-
ute to the observation of increased HPA activity in people 
with more adiposity is that obesity is characterized by a 
state of chronic mild inflammation [25, 26], with enhanced 
circulating levels of inflammatory markers, including 
cytokines [27]. Cytokines  – like stress  – have been shown 
to stimulate the HPA axis at the level of the hypothalamus, 
anterior pituitary gland, and the adrenal cortex [14, 28]. 
 In summary, obesity in humans  – particularly visceral 
obesity  – is associated with increased activity of the HPA 
axis, and this may be due in part to specific qualities of 
visceral adipose tissue. 
 The HPA axis and food intake 
 Before examining the effects of long-term energy restric-
tion, as in  ‘ dieting ’ in obese humans and animals, this 
section provides an overview of the effects of daily 
rhythms in food intake on activity of the HPA axis. This 
knowledge is important, because the recent nutritional 
status of research subjects at the time of investigation can 
profoundly influence results. 
 Food intake has been shown to be a synchronizer of 
diurnal rhythm of the HPA axis, a rhythm that is character-
ized in humans by maximum glucocorticoid levels in the 
early morning and minimum levels at night [29 – 31]. Under 
normal circumstances, surging levels of cortisol enter the 
bloodstream after a midday or evening meal, contributing 
to the undulating nature of daily HPA axis activity [30, 32]. 
 Fasting is a state of stress [29] that alters the normal 
HPA axis rhythm. If overnight fasting is extended through-
out the day, circulating cortisol levels peak later in the 
afternoon and follow an overall higher, flattened profile 
[32 – 34]. This change likely contributes to energy homeo-
stasis in cases of insufficient exogenous energy intake, 
because hypercortisolemia promotes an appetite for cal-
orie-dense, highly palatable food and processes such as 
gluconeogenesis to convert stored forms of energy into 
useable glucose [29, 33, 35 – 38]. 
 The exact mechanism by which the HPA axis responds 
to acute changes in food intake remains elusive. It seems 
that the type of macronutrient ingested plays an impor-
tant role in HPA axis stimulation. High protein meals 
stimulate a significantly higher cortisol secretion than do 
high carbohydrate or high fat meals [39 – 41]. Although sci-
entists are still unclear of how a signal reaches the HPA 
axis once food has been ingested, one study has shown 
that nasogastric compared to intravenous administra-
tion of nutrients induces a much more significant cortisol 
response, suggesting that the signalling emanates from 
the stomach or duodenum before the metabolites enter 
the blood stream [40]. 
 While activity of the HPA axis is influenced by the 
presence of food, human and animal studies (as discussed 
below) have shown that energy restriction, be it severe or 
moderate, also affects the HPA axis on several levels. 
 Effects of energy restriction on 
activity of the HPA axis in obese 
humans 
 A number of studies have looked at the effect of short-
term periods of severe energy restriction on circulating 
or urinary cortisol levels in obese humans, with con-
flicting evidence. Two studies have shown a decrease in 
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circulating cortisol levels, after 48 h [42], or urinary cor-
tisol levels after 3  days [43] of short-term severe energy 
restriction, while three other studies using short-term 
total fasting reported an increase in circulating cortisol 
[44 – 46]. These latter studies involved an 84-h total fast 
[44] or 6 – 11 days of starvation in obese men [45, 46], and 
were found to increase circulating cortisol levels [44 – 46]  – 
both total and unbound [46]  – with no change [45] or only 
a slight increase [46] in total or free urinary cortisol. On 
balance, the majority of the studies (three out of five) that 
have investigated the effects of severe short-term energy 
restriction on circulating cortisol levels in obese humans 
have shown significant increases in this parameter. 
 There have been somewhat mixed results with longer-
term severe energy restriction on HPA axis function in 
obese humans. The majority of studies report no change 
in function. Four weeks of severe energy restriction of 
~380 kcal/day in obese female identical twins had no 
effect on circulating levels of cortisol [47]. In addition, 
a severely energy-restricted diet to achieve a weight loss 
of  > 10% of initial body weight, followed by a 1-week re-
feeding regime, resulted in no change in circulating cor-
tisol levels in obese individuals [48]. Similarly, 3 weeks 
on a severely energy-restricted diet of ~600 kcal/day, fol-
lowed by 1 week of weight maintenance and then 2 weeks 
of ad libitum feeding, did not alter circulating cortisol 
levels in obese men [45]. Further, following 12-weeks on 
a severely energy-restricted diet of 800 kcal/day in obese 
women, circulating ACTH levels and ACTH response to 
ovine CRH stimulation were unaltered relative to pre-diet 
levels and did not differ between the obese participants 
and lean controls [49]. However, in that study cortisol con-
centrations decreased after weight loss, and there was a 
reduced cortisol response to ovine CRH stimulation [49]. 
Another study also showed a decrease in circulating corti-
sol levels in obese males and females following a 4-week 
severely energy-restricted diet of ~380 kcal/day [50]. 
While the majority of studies involving long-term severe 
energy restriction in obese humans have shown either no 
change (three studies) or a decrease (two studies) in cir-
culating cortisol levels or cortisol response, this is not a 
unanimous finding. When obese participants were treated 
with a severely energy-restricted diet of 450 kcal/day for 
16 weeks, followed by a hypocaloric diet for 32 weeks, cir-
culating cortisol levels increased in women, with no sig-
nificant change in men, when measured at 8 and 18 weeks 
after commencing the severely energy-restricted diet [51]. 
 Similar to the findings with longer-term severe 
energy restriction, it is also unclear if longer-term mod-
erate energy restriction, commonly used in the manage-
ment of overweight and obesity, influences circulating 
cortisol levels or function of the HPA axis, with published 
studies reporting no change, inhibitory or stimulatory 
effects. Moderate (30%) energy restriction in overweight 
and obese individuals over a period of 12 weeks resulted 
in no significant differences in 24-h urinary free cortisol/
cortisone, circulating CBG or free cortisol levels during a 
low dose ACTH simulation test [52]. Similarly, 6 months of 
moderate energy restriction (a 250 – 350 kcal/day deficit) 
in obese women had no effect on circulating levels of 
cortisol [53]. These findings support a shorter-term study 
that showed no differences in salivary cortisol levels fol-
lowing 18 days on a moderately energy-restricted diet of 
1000 kcal/day [54]. Also, 3  months on a moderately 
energy-restricted diet of 1000 kcal/day, followed by a 
period where participants were transitioned back to solid-
foods over 2 weeks and then spent 3 months on a weight 
maintenance diet, had no effect on cortisol production 
rate, either absolute values or normalized to fat free mass 
[55]. However, in that study cortisol production rate nor-
malized to fat mass or intra-abdominal fat mass increased 
by 40% and 100%, respectively, after weight loss [55]. 
While these three studies involving moderate energy 
restriction showed no clear changes in HPA axis func-
tion, another study of a 90-day diet of 800 – 1500 kcal/day 
in obese women showed decreased ACTH and cortisol 
levels measured during an oral glucose tolerance test [56]. 
In contrast, moderate energy restriction (a 500 kcal/day 
deficit) over 10 weeks in obese men increased circulating 
cortisol levels and decreased that of ACTH [57]. 
 Taken together, the available literature shows that 
energy restriction in obese adults results in disturbances 
in HPA axis function, albeit the direction of change is not 
clear. In most [44 – 46] but not all [42, 43] studies in obese 
humans, short-term severe energy restriction produced an 
increase in circulating cortisol levels, and this response 
was also seen in women but not men in one longer-term 
study involving severe energy restriction [51]. However, 
most studies involving longer-term severe energy restric-
tion in obese humans showed no change in HPA axis func-
tion [45, 47 ,48], and two studies suggested a decrease in 
activity of this axis [49, 50]. Similarly, longer-term moder-
ate energy restriction in obese humans has been reported 
to result in increases [57], no change [52 – 55] or decreases 
[56, 57] in HPA axis function. 
 A possible explanation for these widely discrepant 
findings in humans could be the time relative to the com-
mencement of energy restriction when HPA axis func-
tion was measured. Many of the studies reviewed in this 
section involved a period of post-diet re-feeding or weight 
maintenance prior to investigation of HPA axis function. 
This experimental paradigm enables the effects of weight 
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loss per se to be examined, independent of any effects of 
energy restriction. Indeed, certain adaptations to energy 
deficit, notably reduced metabolic rate and impaired 
thyroid function, are seen when measured during energy 
restriction but not after a period of 10 days to 3 months in 
energy balance in weight-reduced individuals [58, 59]. As 
such, it is reasonable to propose that HPA axis function 
may be different depending upon whether it is measured 
during energy restriction or following a period of weight 
maintenance at the reduced body weight. Given that obese 
individuals may spend several months in severe or mod-
erate energy restriction in order to reduce excess weight, 
and given that increases in glucocorticoid function can 
have significant effects on fat, lean and bone mass within 
2 – 3  months [60, 61], it is important to assess HPA axis 
function  during energy restriction. Another factor that 
could contribute to the discrepant findings reported in 
this section is negative feedback regulation of the HPA 
axis; initial increases in circulating cortisol levels can 
feed back on the pituitary gland and hypothalamus and 
lead to eventual normalization or even inhibition of the 
axis. Support for this concept comes from a study involv-
ing continuous central administration of neuropeptide Y 
to rats [62], an experimental paradigm that mimics many 
aspects of energy restriction [63]. This paradigm initially 
increased circulating corticosterone and ACTH concen-
trations, but subsequently led to normalization of these 
parameters, as well as down-regulation of hypothalamic 
CRH mRNA expression [62]. In light of these considera-
tions, we propose that a more complete understanding of 
HPA axis function with energy restriction in obese humans 
would be obtained if investigations were made at several 
time points during energy restriction. 
 Effects of energy restriction on 
activity of the HPA axis in obese 
rodents 
 Studies in obese rodents have revealed a profound, pre-
dominantly stimulatory, impact of energy restriction on 
activity of the HPA axis, either when compared to non-
restricted obese controls, or when compared with effects 
of energy restriction in lean rodents. 
 A number of studies have looked into the effect of 
overnight, short-term and longer-term food deprivation 
on corticosterone concentrations in obese mice and rats 
[64 – 67]. These studies showed that following 12 [65], 24 
[66, 67] and 48 [67] h of fasting, or following 3 weeks [64] 
of 33% energy restriction, there was an increase in circu-
lating corticosterone concentrations in obese rodents. A 
similar effect was also seen with longer-term food depriva-
tion. Following a 30% energy-restricted diet for 12-weeks, 
Otsuka Long Evans Tokushima Fatty rats had greater cir-
culating corticosterone concentrations when compared 
with an unrestricted control group [68]. Interestingly, 
in that study no increase in corticosteronemia was seen 
when similar reductions in body weight, adiposity and 
leptinemia were achieved by 12 weeks of wheel running 
[68]. It must be noted that one study in obese mice showed 
a decrease (rather than an increase) in circulating corti-
costerone concentrations following 6-weeks of food dep-
rivation when compared with ad libitum-fed obese mice 
[69]. 
 It can be seen from the above that short- or long-term 
energy restriction in obese rodents generally increases 
circulating corticosterone levels. This effect is likely 
mediated by the hypothalamus, because energy restric-
tion influences hypothalamic expression of CRH or CRH 
receptors in obese rodents. One study looked at the effects 
of 48-h food deprivation on hypothalamic mRNA levels 
of urocortin 3 (Ucn3) and type 2 corticotropin-releasing 
hormone receptor (CRH 2 -R) in lean and obese Zucker rats 
[70]. Ucn3 is part of the CRH family and binds specifically 
to CRH 2 -R to decrease food intake, therefore playing an 
important role in responding to food-related stress. An 
interesting outcome of this experiment was that although 
lean rats showed decreases in hypothalamic Ucn3 and 
CRH 2 -R mRNA levels in response to energy restriction, 
obese Zucker rats showed no change [70]. Similar findings 
were reported in another study, where CRH concentra-
tions were measured in three regions of the hypothala-
mus of lean and obese mice: the arcuate nucleus (ARC), 
paraventricular nucleus (PVN), and ventromedial hypo-
thalamus (VMH). Obese mice had half the CRH concentra-
tions in the ARC as lean mice in the un fasted state, but 
 – unlike their lean counterparts  – they showed no change 
(i.e., no decrease) in ARC CRH concentrations following 
24 h of food deprivation [71]. While these studies showed 
no effect of food deprivation on central CRH expression in 
obese rodents, unlike food-deprived lean animals, another 
study has shown actual increases in brain CRH mRNA 
levels or activation of CRH-expressing hypothalamic cells 
with energy restriction in obese Zucker rats [72]. After 
3, 6, 12 and 24  h of food deprivation, obese Zucker rats, 
compared to lean rats, showed a relative increase in CRH 
mRNA expression or cellular activation of CRH-expressing 
neurons (as indicated by induction of c-fos expression) in 
several brain regions, the changes being most pronounced 
in the PVN. Obese rats also exhibited a marked increase in 
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type 1 corticotropin-releasing hormone receptor (CRH 1 -R) 
mRNA levels in the PVN starting at 6 h after fasting, com-
pared to lean rats, with no significant changes in CRH 2 -R 
[72]. In light of the observation that energy deprivation 
in obese rodents generally increases circulating corticos-
terone levels [64 – 67], these findings of no change  – or an 
actual increase  – in the hypothalamic expression of CRH, 
Ucn3 or their receptors suggest that during energy restric-
tion in obesity, the HPA axis may exhibit impaired nega-
tive feedback regulation at the level of the hypothalamus. 
 While obese rodents generally show energy restric-
tion-induced increases in circulating corticosterone levels 
and no decrease or an actual increase in central expression 
of CRH or CRH receptors, obese mice have been shown to 
have a decreased pituitary content of ACTH following a sig-
nificant period of energy restriction. A group of genetically 
obese  ob/ob mice were put on an energy-restricted diet at 
5 weeks of age, when their weights were slightly over 
normal weight (overweight) [73]. Under normal circum-
stances, adult obese mice were found to have roughly 
14 times higher levels of ACTH in the pituitary gland than 
lean mice. However, after 7 weeks of caloric restriction, 
the obese mice showed pituitary ACTH levels nine times 
less than their obese, non-restricted counterparts, as well 
as a significant decrease in ACTH secretion from the iso-
lated perifused pituitary gland. These differences in pitui-
tary ACTH levels between lean and obese mice were not 
reflected by differences in plasma ACTH and corticosterone 
levels [73]. This study did not report on the effect of energy 
restriction on circulating ACTH levels in obese mice. 
 In summary, the HPA axis of obese rodents shows 
marked changes in response to short- or longer-term 
energy restriction, with most but not all studies showing 
increases in circulating corticosterone concentrations 
compared to non-restricted levels, and no change or 
actual increases in hypothalamic expression of CRH, 
Ucn3 or their receptors. Additionally, one study from 1975 
showed a decrease in pituitary ACTH levels or secretion 
with longer-term energy restriction in obese mice. 
 Effects of changes in activity of the 
HPA axis on body composition 
 It is often assumed that activation of the HPA axis in 
response to energy restriction would only be observed 
under cases of extreme stress, such as in lean humans 
with anorexia nervosa or cachexia, or in lean animals. 
However, our review of the literature in obese humans and 
rodents shows that  – as is the case for the known effects 
of energy restriction on activity of the HPA axis in lean 
humans and animals  – obese humans and rodents some-
times also display enhanced HPA axis activity in response 
to energy restriction. While further work is required to 
confirm this possibility, such an effect could potentially 
contribute to less than optimal changes in body composi-
tion during energy restriction for the treatment of obesity. 
 Not only does the binding of glucocorticoids to glu-
cocorticoid receptors produce effector responses that 
have implications for metabolism and appetite, it also is 
involved in the regulation of adipocyte and myocyte syn-
thesis, as well as regulating osteoblasts and osteoclasts. 
Glucocorticoids, through their interaction with insulin, 
promote the differentiation of pre-adipocytes into mature 
fat cells as well as stimulating lipoprotein lipase activ-
ity, which facilitates fat accumulation, particularly in the 
abdomen [33, 74, 75]. High levels of glucocorticoids inhibit 
myocyte synthesis and promote breakdown through stim-
ulating protein catabolism pathways [33, 76]. This process 
is further accelerated in the absence of insulin [77]. 
This would most likely be seen in the fasting scenario, 
where insulin levels are reduced and the body needs to 
convert stored energy to useable energy [76]. Addition-
ally, the reduced circulating insulin concentrations typi-
cally observed during weight loss interventions in obese 
individuals might therefore be expected to enhance the 
catabolic effects of glucocorticoids on myocytes. Further 
to effects on adipocytes and myocytes, glucocorticoids 
promote apoptosis in osteobalasts and osteocytes, which 
would be expected to decrease bone formation, as well as 
prolonging the lifespan of osteocalsts, which would be 
expected to increase bone resorption [78]. 
 In keeping with the effects of glucocorticoids on fat, 
muscle and bone cells observed in vitro, lean men and 
women taking a high dose of oral glucocorticoid treatment 
(  ≥  40 mg/day of a prednisolone equivalent) for 2 months 
showed a 10% increase in fat mass, a 10% decrease in lean 
body mass, and significant decreases in bone mineral 
density and bone mineral content in the absence of effects 
on body weight [60]. Longer-term use (more than 60 days) 
of oral glucocorticoids is associated with self-reported 
weight gain in over 60% of patients, including those on 
lower doses (e.g., 10  mg/day prednisone for 6 months), 
and weight gain is the most commonly reported adverse 
event in patients taking glucocorticoids [61]. Additionally, 
people with Cushing ’ s syndrome, associated with primary 
hypercortisolism, exhibit hyperphagia, weight gain, vis-
ceral obesity and muscle wasting [19, 76, 79], further 
demonstrating a primary role of increased glucocorticoid 
action in the propensity to store fat (particularly central 
fat) at the expense of lean tissues. 
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 It remains to be determined whether any changes in 
circulating glucocorticoid concentrations with energy 
restriction in obese individuals contributes to adverse 
effects on body composition. 
 The gap in knowledge and 
significance 
 Our review of the literature has not ruled out the possi-
bility that energy restriction in obese individuals is per-
ceived as a nutritional stress, resulting in indications of 
enhanced HPA axis function in most rodent studies and in 
some  – but certainly not all  – human studies. Studies in 
obese humans on effects of energy restriction on HPA axis 
function showed a great deal of variability, with reports 
of increased, unchanged or decreased circulating cortisol 
levels. As recent nutritional status influences function of 
the HPA axis, and because changes in HPA axis activity 
can be masked by feedback regulation of the axis by gluco-
corticoids, we propose that a more complete understand-
ing of HPA axis function with energy restriction in obese 
humans would be obtained if investigations were made at 
several time points  during energy restriction, as opposed 
to after a period of post-restriction re-feeding, as was the 
case in several human studies hereby reviewed. Addi-
tionally, correlating changes in HPA axis function with 
changes in parameters of body composition, such as fat 
mass and distribution, lean body mass, muscle strength 
and bone mineral content, could shed light on the role of 
altered HPA axis function, if any, in mediating favourable 
or unfavourable changes in body composition in response 
to obesity treatments. Such knowledge could aid in the 
quest for obesity treatments that maximize the loss of fat 
mass, particularly abdominal or visceral fat mass, without 
compromising lean body mass or bone mass. 
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